FROM today patients now have
access to Invenga Sustenna
(paliperidone palmitate) on the
Pharmaceutical Benefits Scheme.
Invenga Sustenna is a oncemonthly,
long-acting injectable
antipsychotic for both the acute
and maintenance treatment of
schizophrenia in adults.
According to clinical trials the
drug offers significant reductions in
relapse rates (10%) compared to a
placebo (34%).
The listing follows the drug’s PBS
deferral in February.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Dec 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Dec 11
OVER a quarter of a million people have sbeen vaccinated against influenza this year through community pharmacies in Queensland, reported the Pharmacy Guild of Australia.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.